

Summer Breeze「夏天小语」 Trading buy opportunity in Biostime (1112 HK)

Consumer Staples Sector

We identify a trading buy opportunity in Biostime (1112 HK, Neutral, TP raised to HK30.00 from HK\$27.00) despite staying Neutral on the stock. Three reasons for our arguments: (1) Biostime's 2014 results are likely to beat consensus on tighter-than-expected expense control in 2H14. (2) Reduced dairy cost (c30% of Biostime's COGS, in our estimate) coupled with lower shipping cost and weakening euro should lead to visible gross margin expansion (vs. flat in current Street estimates) in 2015E, all else being equal. Note Mead Johnson (MJN US) has already guided to a 1.6-ppt gross margin improvement in 2015E on lower commodity costs. (3) Biostime started to lose sales momentum from 2014 given the fast channel shift to ecommerce, reversing its winner position amid the booming emergence of baby stores nationwide in the past. Such a situation, in our view, should motivate management to close financing deals with strategic investors at Mama100 level asap, following the company announcement in Feb 2015. Despite that we do not think the participation of strategic investor(s) to Mama100 necessarily translate to the success of Biostime's ecommerce venture, this may help change Biostime's investment profile from a pure infant milk formulae (IMF) player into a more integrated and diversified baby FMCG operator (particularly if it can differentiate in products). Given the likely margin-led earnings upgrades and business model enhancement, a trading buy opportunity could emerge from the stock, in our opinion.

- We raise our 2014-16E core net profit by 9%-12% on margins. Thanks to (1) favorable dairy cost (with market prices down c30% YTD vs 2014 average prices), (2) falling fuel oil prices (down 45% YTD) and (3) weakening euro (down 14% YTD vs 2014 average levels), we project Biostime's imported IMF gross margin to improve by 2-ppt to 63.5% in 2015E after factoring in the ASP pressure. Combined with the possibility of upbeat management guidance on margins during the analyst meeting (due on 25 Mar), the Street could lift margin assumptions, in our view. On the other hand, we presently remain cautious about Biostime's revenue generation given the "volume" challenge ahead amid competition, and adjust down our revenue forecasts by 1%-7% in 2014-16E. (See our earnings forecast revision on page 3)
- Why "trading buy" instead of BUY? The proliferation of online channels and an overall slowing market have put Biostime at a tougher situation given its higher ASP and "generous" profit allocation to offline channels (rather than to end-consumers). Biostime's inflection point is yet to be seen, though we are largely positive on its intention to penetrate ecommerce on baby products via its Mama100.com. The upcoming action may help gradually lift Biostime's investment profile to a more integrated and diversified baby FMCG player (if executed well). However, we have to highlight two risks as well: (1) GMV bottleneck. E-commerce giants like Jingdong.com (JD US) have cost advantage over specialized Biostime unless Biostime can clearly differentiate, in our view. The participation of strategic investors is also by no means the guarantee of Biostime's success in ecommerce; (2) Profit concern. Despite the popularity of baby ecommerce player in the private equity market, few are making money, in our guess. The harvest period is yet to come. Therefore, at this moment, we rate Biostime at Trading Buy/Neutral (before further visibility is identified) with TP raised to HK\$30.00 (from HK\$27.00) on unchanged 20x our revised 2015E EPS.

Summer Wang

summer.wang@bocomgroup.com Tel: +852 2977 9221


**Summer Breeze, launched by our consumer analyst Summer Wang, is a unique research product designed to offer investors with actionable ideas in the China Consumer Staples sector.



Visible gross margin expansion on imported IMF in 2015E


(on lower dairy prices, shipping cost and weakening euro, all else being equal)

Figure 1: Europe skim and whole milk powder prices 2004-YTD (down c30% YTD vs 2014 average)



Source: Bloomberg

Figure 3: Mead Johnson's COGS breakdown 2014; we think Biostime's COGS mix should be similar.




Source: Company data

Figure 5: RMB/Euro exchange rate (down 14% YTD vs 2014 average levels)



Figure 2: Europe whey powder prices 2004-YTD (down 15% YTD vs 2014 average)



Source: Bloomberg

Figure 4: Lower fuel prices (down 45% YTD vs 2014 average) should help reduce shipping cost, in our view.





Figure 6: Biostime's 12-forward P/E 2011-YTD






Raise 2014-16E core net profit by 9%-12% on margins

Figure 7: Biostime's earnings forecast revision 2014-16E

(RMBm, Year ending 31 Dec)20072008Total Revenue188326Infant formulas (imported)041Infant formulas (China manufactured)00Probiotic supplements172254Dried baby food and nutrition supplements1631Baby care products00Yo' growthNA73%Total RevenueNA73%Infant formulas (imported)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNANAOried baby food and nutrition supplementsNA91%Baby care productsNANAGross profit138237Yo' growthNA72%Blended gross margin73.2%72.8%Infant formulas (China manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Bended gross margin73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Bibri formulas (China manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Bibri formulas (China manufactured)NANA </th <th>2009 559 238 0 266 55 0 72% 483% NA 5% 78%</th> <th>1,234 3 794 0 0 5 304 6 98 0 38</th> <th>2011 2,189 1,685 0 332 125 48</th> <th>2012 3,382 2,715 0 379 181</th> <th>2013 4,561 3,752 0 458</th> <th>1H14 2,189 1,859 0</th> <th>2H14E 2,364 1,969 31</th> <th>2014E 4,553 3,828</th> <th>2015E 5,081 3,962</th> <th>2016E 5,523 4,160</th> <th>2014E -1%</th> <th>2015E -4%</th> <th>2016E -7%</th>	2009 559 238 0 266 55 0 72% 483% NA 5% 78%	1,234 3 794 0 0 5 304 6 98 0 38	2011 2,189 1,685 0 332 125 48	2012 3,382 2,715 0 379 181	2013 4,561 3,752 0 458	1H14 2,189 1,859 0	2H14E 2,364 1,969 31	2014E 4,553 3,828	2015E 5,081 3,962	2016E 5,523 4,160	2014E -1%	2015E -4%	2016E -7%
Infant formulas (imported)041Infant formulas (China manufactured)00Probiotic supplements172254Baby care products00Yoy growth00Total RevenueNA73%Infant formulas (imported)NANAInfant formulas (imported)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNANAGross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NANAInfant formulas (imported)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements73.5%72.8%Grosseree0013.1%Di	238 0 266 55 0 72% 483% NA 5%	3 794 0 0 3 304 9 98 0 38	1,685 0 332 125	2,715 0 379 181	3,752 0	1,859 0	1,969	3,828	-				
Infant formulas (China manufactured)00Probiotic supplements172254Dried baby food and nutrition supplements1631Baby care products00YOY growthNA73%Infant formulas (imported)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNANAGross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NANAProbiotic supplements73.5%74.9%Infant formulas (China manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%Distribution costs50.5%51.9%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Timance costs00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%<	0 266 55 0 72% 483% NA 5%	0 0 5 304 5 98 0 38	0 332 125	0 379 181	0	0			3,962				5.0/
Probiotic supplements172254Dried baby food and nutrition supplements1631Baby care products00Yot growthNA73%Total RevenueNA73%Infant formulas (China manufactured)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNA47%Gross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NANAInfant formulas (China manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Blended gross margin73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements70.3%67.2%Belt2744YoY growthNA62.7%EBIT margin14.3%13.5%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA<	266 55 0 72% 483% NA 5%	5 304 5 98 0 38	332 125	379 181					272		-1%	-3%	-5%
Dried baby food and nutrition supplements1631Baby care products00YOY growthNA73%Infant formulas (imported)NANAInfant formulas (China manufactured)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNA72%Gross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NANAInfant formulas (imported)NA64.0%Infant formulas (imported)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBITmargin14.3%13.5%Operating expenses5.90%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses5.3%6.2%Cher operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	55 0 72% 483% NA 5%	i 98) 38	125	181	458	400		31	373	560	0%	-23%	-25%
Baby care products00Yo' growthNA73%Total RevenueNA73%Infant formulas (imported)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNA72.8%Gross profit138237YO' growthNA72.8%Blended gross margin73.2%72.8%Infant formulas (imported)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YO' growthNA62.7%EBIT margin13.5%59.0%Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses5.3%6.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YO' growthNA101%Core net profit1735	0 72% 483% NA 5%	38				186	189	376	398	422	0%	0%	0%
YoY growthTotal RevenueNAInfant formulas (China manufactured)NANAProbiotic supplementsNAProbiotic supplementsNADried baby food and nutrition supplementsNABaby care productsNAGross profit138138237YoY growthNAReded gross margin73.2%Infant formulas (imported)NAInfant formulas (imported)NAInfant formulas (China manufactured)NAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%For Way GrowthRAProbiotic supplements70.3%For Way GrowthNAProbiotic supplements70.3%For Way GrowthNAEBIT2744YOy growthCoperating expenses59.0%Distribution costs50.5%Jistribution costs50.5%Admin expenses5.3%6.2%0Chinance costs000Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthCore net profit1735	72% 483% NA 5%		48		199	71	73	143	146	153	0%	0%	0%
Total RevenueNA73%Infant formulas (imported)NANAInfant formulas (China manufactured)NANAProbiotic supplementsNA91%Baby care productsNA91%Baby care productsNA72%Gross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (china manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT argin14.3%13.5%Operating expenses5.9.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	483% NA 5%	12404		106	152	73	102	175	201	228	0%	0%	0%
Infant formulas (imported)NANAInfant formulas (China manufactured)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (imported)NA64.0%Infant formulas (china manufactured)NANAProbiotic supplements73.5%74.9%Baby care productsNA64.2%EBIT2744YoY growthNA62.7%EBIT2744YoY growthNA62.7%EBIT2744YoY growthNA62.7%EBIT mergin14.3%13.5%Ø of Revenue50.5%51.9%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses5.3%6.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	483% NA 5%			/									
Infant formulas (China manufactured)NANAProbiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNANAGross profit138237Y0Y growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAProbiotic supplements70.3%67.2%Baby care productsNANAEBIT2744Y0Y growthNA62.7%Baby care products59.0%59.3%Distribution costs50.5%51.9%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses3.3%6.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735Y0Y growthNA101%Core net profit1735	NA 5%		77%	54%	35%	6%	-5%	0%	12%	9%			
Probiotic supplementsNA47%Dried baby food and nutrition supplementsNA91%Baby care productsNANAGross profit138237Yoy growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (imported)NA64.2%Probiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YOy growthNA62.7%EBIT margin14.3%13.5%Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.3%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthNA101%Core net profit1735	5%		112%	61%	38%	11%	-5%	2%	3%	5%			
Dried baby food and nutrition supplementsNA91%Baby care productsNANAGross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (China manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT gexpenses59.0%59.3%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Tinance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735			NA	NA	NA	NA	NM	NM	1100%	50%			
Baby care productsNANAGross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (china manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements73.5%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT margin14.3%13.5%% of Revenue50.5%51.9%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	/8%		9%	14%	21%	-18%	-18%	-18%	6%	6%			
Gross profit138237YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (china manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT margin14.3%13.5%Ø of Revenue59.0%59.3%Operating expenses59.0%59.3%Other operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735			27%	46%	10%	-19%	-35%	-28%	2%	5%			
YoY growthNA72%Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (thin anaufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT margin14.3%13.5%Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	NA	A NA	24%	122%	44%	15%	15%	15%	15%	13%			
Blended gross margin73.2%72.8%Infant formulas (imported)NA64.0%Infant formulas (china manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT margin14.3%13.5%Ø of Revenue50.5%51.9%Operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	396	6 877	1,456	2,229	2,975	1,346	1,435	2,781	3,138	3,390	-1%	0%	-3%
Infant formulas (imported)NA64.0%Infant formulas (China manufactured)NANAProbicitic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT mergin14.3%13.5%Ø of Revenue50.5%51.9%Operating expenses5.3%6.2%Other operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	67%	5 122%	66%	53%	33%	-2%	-11%	-7%	13%	8%			
Infant formulas (China manufactured)NANAProbiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YOY growthNA62.7%EBIT margin14.3%13.5%Øperating expenses59.0%59.3%Distribution costs50.5%51.9%Other operating expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthNA101%Core net profit1735	70.8%	5 71.1%	66.5%	65.9%	65.2%	61.5%	60.7%	61.1%	61.8%	61.4%	\uparrow	\uparrow	\uparrow
Probiotic supplements73.5%74.9%Dried baby food and nutrition supplements70.3%67.2%Baby care productsNANAEBIT2744YoY growthNA62.7%EBIT margin14.3%13.5%Ø operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	67.3%	68.4%	65.5%	65.1%	64.5%	61.7%	61.4%	61.5%	63.5%	63.5%	\uparrow	\uparrow	\uparrow
Dried baby food and nutrition supplements70.3% NA67.2% Baby care products67.2% NABBIT2744 YOY growthNA62.7%EBIT margin14.3% S of Revenue13.5% S 59.3%59.3% S 59.3%62.8% C 59.3%Operating expenses5.3% S 6.2% Other operating expenses5.3% S 6.2%6.2% C 00Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2% S 21.2%21.2%Reporeted net profit YoY growth1735 YOY growthCore net profit1735	NA	NA NA	NA	NA	NA	NA	50.0%	50.0%	51.0%	51.0%			
Baby care productsNANAEBIT2744YOY growthNA62.7%EBIT margin14.3%13.5%% of Revenue70013.5%Operating expenses50.5%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthNA101%Core net profit1735	76.5%	81.9%	77.8%	77.7%	78.6%	71.6%	71.0%	71.3%	71.0%	72.0%			
EBIT2744YoY growthNA62.7%EBIT margin14.3%13.5%% of Revenue14.3%13.5%Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	58.9%	65.9%	60.2%	59.1%	55.6%	46.0%	44.0%	45.0%	44.0%	43.0%			
YoY growthNA62.7%EBIT margin14.3%13.5%% of Revenue	NA	55.6%	40.2%	54.9%	54.2%	46.0%	44.3%	45.0%	42.0%	41.0%			
EBIT margin14.3%13.5%% of Revenue%Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	117	332	697	1,008	1,248	425	501	925	1,011	1,082	9%	11%	8%
EBIT margin14.3%13.5%% of Revenue%Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	167.7%	182.7%	109.9%	44.7%	23.8%	-31.0%	-20.8%	-25.8%	9.3%	7.0%			
% of RevenueOperating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735Yo'g growthNA101%Core net profit1735	21.0%		31.8%	29.8%	27.4%	19.4%	21.2%	20.3%	19.9%	19.6%			
Operating expenses59.0%59.3%Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthNA101%Core net profit1735													
Distribution costs50.5%51.9%Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective tax rate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	50.2%	44.4%	37.2%	36.5%	38.3%	42.3%	39.3%	40.8%	41.9%	41.8%	\downarrow	\downarrow	\downarrow
Admin expenses5.3%6.2%Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthNA101%Core net profit1735	44.4%	36.4%	32.4%	31.9%	33.2%	36.6%	34.3%	35.4%	36.6%	36.5%			
Other operating expenses3.2%1.2%Fine on the violation of Anti-monopoly law00Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YOY growthNA101%Core net profit1735	4.7%	5 7.1%	3.7%	3.5%	3.9%	3.9%	3.6%	3.8%	3.8%	3.8%			
Finance costs00Effective taxrate36.2%21.2%Reporeted net profit1735YoY growthNA101%Core net profit1735	1.1%		1.1%	1.1%	1.2%	1.8%	1.4%	1.6%	1.5%	1.5%			
Effective taxrate 36.2% 21.2% Reporeted net profit 17 35 Yo' growth NA 101% Core net profit 17 35	0	0 0	0	0	-163	0	0	0	0	0			
Reporeted net profit 17 35 YoY growth NA 101% Core net profit 17 35	0	0	0	-2	-11	-40	-51	-91	-103	-105			
YoY growth NA 101% Core net profit 17 35	8.3%	20.5%	26.1%	29.3%	29.4%	27.9%	26.2%	27.0%	27.0%	27.0%			
YoY growth NA 101% Core net profit 17 35	108	266	527	743	821	312	366	678	745	800	9%	12%	9%
Core net profit 17 35	209%		98%	41%	10%	5%	-30%	-17%	10%	7%	2.0		270
-	108		527	743	984	312	366	678	745	800	9%	12%	9%
	208%		98%	41%	32%	-32%	-30%	-31%	10%	7%	2.2		270
Core net margin 9.3% 10.8%	19.4%		24.1%	22.0%	21.6%	14.3%	15.5%	14.9%	14.7%	14.5%			
Change in ppts NA 1.5%	8.6%		2.6%	-2.1%	-0.4%	-8.1%	-5.4%	-6.7%	-0.2%	-0.2%			
Reported diluted EPS (RMB) 0.04 0.08		0.58	0.86	1.22	1.34	0.51	0.59	1.10	1.20	1.29	8%	11%	8%
YoY growth NA 101%	0.24		49%	41%	1.54	5%	-30%	-18%	9%	7%	070	11/0	070
Core diluted EPS (RMB) 0.04 0.08	0.24		0.86	1.22	1.60	0.51	0.59	1.10	1.20	1.29	8%	11%	8%
YoY growth NA 101%	0.24 209% 0.24	5 141%	49%	41%	32%	-32%	-30%	-31%	9%	7%	078	11/0	070


Source: Company data, BOCOM Int'l estimates





Source: Company data, BOCOM Int'l estimates

Figure 9: Biostime's margins 2007-16E



Source: Company data, BOCOM Int'l estimates



Financial Statements

Figure 10: Biostime - Financial summary 2008-16E

(RMBm, Year ending 31 Dec)	2008	2009	2010	2011	2012	2013	2014E	2015E	2016E
P&L									
Total Revenue	326	559	1,234	2,189	3,382	4,561	4,553	5,081	5,523
Infant formulas (imported)	41	238	794	1,685	2,715	3,752	3,828	3,962	4,160
Infant formulas (China manufactured)	0	0	0	0	0	0	31	373	560
Other baby products	285	321	440	504	667	809	694	746	803
Gross profit	237	396	877	1,456	2,229	2,975	2,781	3,138	3,390
EBIT	44	117	332	697	1,008	1,248	925	1,011	1,082
Reported PBT	45	118	334	714	1,051	1,162	929	1,021	1,096
Effective taxrate	21.2%	8.3%	20.5%	26.1%	29.3%	29.4%	27.0%	27.0%	27.0%
Reporeted net profit	35	108	266	527	743	821	678	745	800
Core net profit	35	108	266	527	743	984	678	745	800
Reported diluted EPS (RMB)	0.08	0.24	0.58	0.86	1.22	1.34	1.10	1.20	1.29
Core diluted EPS (RMB)	0.08	0.24	0.58	0.86	1.22	1.60	1.10	1.20	1.29
DPS (RMB)	NA	NA	0.200	0.618	0.879	0.963	0.786	0.860	0.923
Dividend payout	0.0%	0.0%	38.2%	70.6%	70.9%	70.4%	70.0%	70.0%	70.0%
Cash flow			204				400	4 5 7 9	
Net operating cash flow	23	110	381	516	947	660	-100	1,573	99
Capex	-11	-6	-18	-39	-39	-138	-300	-127	-110
Acquisitions	0	0	0	0	0	-280	0	0	0
Change in loans and bond receivable	0	0	0	0	-122	-89	-8	-16	-13
Change in time deposits	-1	-5	6	-484	-1,727	388	0	0	0 0
Change in deposits	-1	-5	6	-21	-3	0	0	0	
Interest received	1	1	2	14	29	60	95	112	119
Other investing cash	-2	-10	12	-21	8	-21	0	0	0
Net investing cash flow	-14	-20	3	-529	-1,850	-81	-213	-30	-5
Net proceeds from share issuance	0 0	0	1,372	12 0	-57 271	-64 480	0 -150	0 0	0
Net proceeds from bank borrowings		1	-1						
Convertible bond	0 0	0 0	0	0 0	0	0	2,480 -91	0	0
Interest paid	-13	-27	0 -146	-180	-1 -404	-9 -622	-91	-103 -486	-105 -531
Dividends paid Other financing cash	-13	-27	-140	081-	-404	-022	-470	-480	-551
Net financing cash flow	0	-26	1,231	- 169	- 192	-215	1,763	-588	-635
-	9	-20	1,231			-215	-	-588 954	-541
Net change in cash and cash equivalents Balance sheet	9	04	1,015	-182	-1,095	305	1,451	954	-541
Cash and bank balances	60	134	1,728	1,814	1,669	1,663	3,113	4,068	3,527
Inventory	44	81	106	297	523	972	1,703	1,083	1,814
Trade and bills receivables	6	4	5	10	0	15	10	1,005	1,014
Prepayments, deposits and other receivables	14	21	23	29	86	111	109	122	127
Other current assets	23	14	0	0	13	105	105	103	106
Total current assets	147	254	1,862	2,150	2,291	2,866	5,041	5,383	5,585
Net PPE	22	22	31	59	77	326	550	596	622
Prepaid land lease payment	0	0	0	0	20	65	83	101	119
Intangible assets	1	1	1	1	1	110	111	114	116
Goodwill	0	0	0	0	0	76	76	76	76
Bonds receivable	0	0	0	0	0	98	100	112	120
Loans receivable	0	0	0	0	110	85	91	97	99
Time deposits	0	0	0	160	942	855	855	855	855
Other non-current assets	5	7	7	67	91	160	160	160	160
Total non-current assets	28	30	40	288	1,242	1,775	2,026	2,109	2,167
Total assets	175	283	1,902	2,438	3,533	4,641	7,067	7,492	7,752
Trade and bill payables	18	40	66	67	263	362	338	429	412
Other payables and accruals	44	64	142	265	444	720	637	711	718
Dividend payable	0	0	0	0	0	0	0	0	0
Interest-bearing bank loans	0	1	0	0	271	751	601	601	601
Taxpayable	7	9	28	83	156	213	213	213	213
Other current liabilities	17	0	0	0	0	0	0	0	0
Total current liabilities	87	113	236	415	1,133	2,045	1,788	1,954	1,944
Deferred tax liabilities	0	0	6	45	77	81	81	81	81
Total liabilities	87	113	242	461	1,211	2,125	4,349	4,514	4,504
Total equity	89		1,660						
Iotal equity	07	171	1,000	1,978	2,323	2,516	2,718	2,978	3,248

Source: Company data, BOCOM Int'l estimates



Figure 11: Biostime - Key ratios 2008-16E

Year ending 31 Dec	2008	2009	2010	2011	2012	2013	2014E	2015E	2016E
YoY growth									
Total revenue	73%	72%	121%	77%	54%	35%	0%	12%	9%
Infant formulas (imported)	NA	483%	233%	112%	61%	38%	2%	3%	5%
Infant formulas (China manufactured)	NA	NA	NA	NA	NA	NA	NM	1100%	50%
Other baby products	NA	13%	37%	15%	32%	21%	-14%	7%	8%
Gross profit	72%	67%	122%	66%	53%	33%	-7%	13%	8%
EBIT	63%	168%	183%	110%	45%	24%	-26%	9%	7%
EBITDA	65%	163%	177%	109%	45%	24%	-23%	9%	7%
Reported PBT	63%	165%	183%	114%	47%	11%	-20%	10%	7%
Reporeted net profit	101%	209%	145%	98%	41%	10%	-17%	10%	7%
Core net profit	101%	208%	145%	98%	41%	32%	-31%	10%	7%
Reported diluted EPS	101%	209%	141%	49%	41%	10%	-18%	9%	7%
Core diluted EPS	101%	208%	141%	49%	41%	32%	-31%	9%	7%
Margins									
Blended gross margin	72.8%	70.8%	71.1%	66.5%	65.9%	65.2%	61.1%	61.8%	61.4%
EBIT margin	13.5%	21.0%	26.9%	31.8%	29.8%	27.4%	20.3%	19.9%	19.6%
EBITDA margin	14.3%	21.9%	27.5%	32.4%	30.5%	27.9%	21.6%	21.1%	20.7%
Reported PBT margin	13.7%	21.1%	27.1%	32.6%	31.1%	25.5%	20.4%	20.1%	19.8%
Reported net margin	10.8%	19.4%	21.5%	24.1%	22.0%	18.0%	14.9%	14.7%	14.5%
Core net margin	10.8%	19.4%	21.5%	24.1%	22.0%	21.6%	14.9%	14.7%	14.5%
Returns									
ROE (average)	54.4%	83.6%	29.0%	29.0%	34.6%	33.9%	25.9%	26.2%	25.7%
ROA (average)	25.1%	47.2%	24.3%	24.3%	24.9%	20.1%	11.6%	10.2%	10.5%
ROIC	39.0%	62.9%	15.8%	25.4%	26.7%	26.3%	11.5%	12.0%	12.3%
Working capital									
Average inventory days	118	140	96	100	130	172	200	190	180
Average AR days	8	3	1	1	1	1	1	1	1
Average AP days	45	65	54	33	52	72	72	72	72
Cash conversion days	80	78	43	69	78	101	129	119	109
Leverage									
Current ratio	5.3x	8.5x	46.7x	7.5x	1.8x	1.6x	2.5x	2.6x	2.6x
Assets / Equity	1.7x	1.5x	1.1x	1.1x	1.0x	1.1x	1.9x	1.8x	1.7x
Gross gearing	0%	0%	0%	0%	12%	30%	113%	103%	95%
Net cash / Equity	67%	78%	104%	92%	60%	36%	1%	33%	14%
Dupont analysis									
Net profit /EBIT	80.0%	92.3%	80.1%	75.7%	73.7%	65.8%	73.3%	73.7%	74.0%
EBIT/EBITDA	94.5%	96.1%	97.9%	98.2%	97.8%	97.9%	94.2%	94.3%	94.4%
EBITDA margin	14.3%	21.9%	27.5%	32.4%	30.5%	27.9%	21.6%	21.1%	20.7%
Asset turnover	1.9x	2.0x	0.6x	0.9x	1.0x	1.0x	0.6x	0.7x	0.7x
Financial leverage	1.7x	1.5x	1.1x	1.1x	1.0x	1.1x	1.9x	1.8x	1.7x
ROE (year end)	33.3%	56.8%	15.7%	23.5%	20.7%	20.1%	17.8%	18.0%	17.7%
Valuation (on current price)									
P/E					11.6x	10.5x	12.8x	11.7x	10.9x
P/B					3.7x	3.4x	3.2x	2.9x	2.7x
P/S					2.5x	1.9x	1.9x	1.7x	1.6x
EV/Sales					3.4x	2.5x	2.5x	2.2x	2.1x
ev/ebitda					11.1x	9.0x	11.6x	10.6x	10.0x
Dividend yield					6%	7%	6%	6%	7%
FCF yield Source: Company data_BOCOM Int'l estimates					11%	6%	-5%	17%	0%

Source: Company data, BOCOM Int'l estimates, valuation based on HK\$24.90 as of market close on 20 Mar, 2015.



Main: + 852 37	10 2220	Eave 1.0	52 3798 0133		ncom	
Main: + 852 37	10 3328	Fax: + 6	52 3798 0133	www.bocomgrou	p.com_	
Rating System						
Company Rating				Sector Rating		
Buy: Expect more tha	n 20% upsid	e in 12 months		Outperform ("OP"): Exp	ect more than 10% upside i	n 12 months
LT Buy: Expect more t	han 20% up	side but longer th	an 12 months	Market perform ("MP")		
Neutral: Expect low v				Underperform ("UP"): Ex	pect more than 10% downs	ide in 12 months
Sell: Expect more that	n 20% down	side in 12 months	;			
Research To	eam					
Head of Research			@bocomgroup.com			@bocomgroup.com
Raymond CHENG, CFA,	CPA, CA (852) 2977 9393	raymond.cheng			
Strategy				Economics		
Hao HONG, CFA	(852) 2977 9384	hao.hong	Miaoxian Ll	(86) 10 8800 9788 - 8043	miaoxian.l
Banks				Oil & Gas/ Gas Utili	ties	
Qingli YANG	(852) 2977 9212	yangqingli	Fei WU	(852) 2977 9392	fei.wu
Shanshan Ll		800 9788 - 8058	lishanshan	Tony LIU	(852) 2977 9390	xutong.liu
Li WAN	(86) 10 88	800 9788 - 8051	wanli			
Consumer Discretio	onary			Property		
Phoebe WONG		852) 2977 9391	phoebe.wong	Alfred LAU, CFA, FRM	(852) 2977 9235	alfred.lau
Anita CHU	(852) 2977 9205	anita.chu	Philip TSE, CFA, FRM	(852) 2977 9220	philip.tse
				Luella GUO	(852) 2977 9211	luella.guo
Consumer Staples				Renewable Energy		
Summer WANG	(852) 2977 9221	summer.wang	Louis SUN	(86) 21 6065 3606	louis.sur
Shawn WU	(852) 2977 9386	shawn.wu			
Healthcare				Telecom & Small/ N	1id-Caps	
Milo LIU	(852) 2977 9387	milo.liu	Zhiwu Ll	(852) 2977 9209	lizhiwu
Insurance				Technology		
Jerry Ll	(852) 2977 9389	liwenbing	Miles XIE	(852) 2977 9216	miles.xie
Jennifer ZHANG	(852) 2977 9250	yufan.zhang			
Internet				Transportation & In	dustrial	
Yuan MA	(86) 10 8	800 9788 - 8039	yuan.ma	Geoffrey CHENG, CFA	(852) 2977 9380	geoffrey.cheng
Connie GU, CPA	(86) 10 8	800 9788 - 8045	conniegu	Fay Zhou	(852) 2977 9381	fay.zhou
Metals & Mining				Automobile		
Jovi Ll		852) 2977 9243	jovi.li	Wei YAO	(86) 21 6065 3675	wei.yad



Analyst Certification

The authors of this report, hereby declare that: (i) all of the views expressed in this report accurately reflect their personal views about any and all of the subject securities or issuers; and (ii) no part of any of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report; (iii) no insider information/ non-public price-sensitive information in relation to the subject securities or issuers which may influence the recommendations were being received by the authors.

The authors of this report further confirm that (i) neither they nor their respective associates (as defined in the Code of Conduct issued by the Hong Kong Securities and Futures Commission) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of the report; (ii)) neither they nor their respective associates serve as an officer of any of the Hong Kong listed companies covered in this report; and (iii) neither they nor their respective associates have any financial interests in the stock(s) covered in this report.

Disclosure of relevant business relationships

BOCOM International Securities Limited, and/or its associated companies, has investment banking relationship with Bank of Communications, Harbin Bank Co., Ltd., Azure Orbit International Finance Limited, Hanhua Financial Holding Co., Ltd., Central China Securities Company Limited, China New City Commercial Development Limited, China Shengmu Organic Milk Limited, Broad Greenstate International Company Limited, China National Culture Group Limited, Sichuan Development Holding Co. Ltd., Austar Lifesciences Limited and BAIC Motor Corporation Limited within the preceding 12 months.

BOCOM International Holdings Company Limited currently holds more than 1% of the equity securities of Shanghai Fosun Pharmaceuticals Group Co. Ltd.

BOCOM International Securities Limited currently holds more than 1% of the equity securities of Sanmenxia Tianyuan Aluminum Company Limited.

Disclaimer

By accepting this report (which includes any attachment hereto), the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of law.

This report is strictly confidential and is for private circulation only to clients of BOCOM International Securities Ltd. This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of BOCOM International Securities Ltd.

BOCOM International Securities Ltd, its affiliates and related companies, their directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be interested in, any such securities. Further, BOCOM International Securities Ltd, its affiliates and its related companies may do and seek to do business with the company(ies) covered in this report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking, advisory, underwriting, financing or other services for or relating to such company(ies) as well as solicit such investment, advisory, financing or other services from any entity mentioned in this report. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

The information contained in this report is prepared from data and sources believed to be correct and reliable at the time of issue of this report. This report does not purport to contain all the information that a prospective investor may require and may be subject to late delivery, interruption and interception. BOCOM International Securities Ltd does not make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report and accordingly, neither BOCOM International Securities Ltd nor any of its affiliates nor its related persons shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst BOCOM International Securities Ltd's clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments thereof.

The views, recommendations, advice and opinions in this report may not necessarily reflect those of BOCOM International Securities Ltd or any of its affiliates, and are subject to change without notice. BOCOM International Securities Ltd has no obligation to update its opinion or the information in this report.

Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to any law, regulation, rule or other registration or licensing requirement.

BOCOM International Securities Ltd is a wholly owned subsidiary of Bank of Communications Co Ltd.